Olsalazine (H.sub.4olz), a prodrug of the anti-inflammatory 5-aminosalicylic acid, is used as a ligand to synthesize a suite of M(H.sub.2olz) and M.sub.2(olz) materials, where M is a dication (e.g. Mg, Ca, Sr, Fe, Co, Ni, Cu, Zn). A family of metal olsalazine coordination polymers, coordination solids, and metal organic frameworks are described, which include 1-, 2-, and 3-dimensional structures. The materials resist degradation at acidic pH and release olsalazine preferentially at neutral pH. The mesoporous M.sub.2(olz) frameworks exhibit high surface areas with hexagonal pore apertures that are approximately 27 Å in diameter and contain coordinatively unsaturated metal sites. Biologically active molecules containing a Lewis-basic functional group can be grafted directly to the open metal sites of the frameworks. Dissolution of the frameworks under physiological conditions releases olsalazine (H.sub.4olz) and the grafted molecules so that multiple therapeutic components can be delivered together at different rates.

The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.

The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.

The present disclosure provides a process of producing a dry powder coated pharmaceutical capsule. The method includes preparing a dry powder film forming polymer coating composition to be coated onto an outer surface of the capsules, a size of the particulate coating powder being in a range from about 1 nm to about 500 m. The capsules are placed into an interior of a rotatable housing and may be preheated. The dry powder coating composition is sprayed into the interior of the housing while the rotatable housing is rotating to produce a uniform coating of the dry powder coating composition on the outer surface of the capsules. The coated capsules are cured form a substantially uniform cured.

The present disclosure provides layer-by-layer compositions comprising a plurality of polymer bilayers. Each bilayer comprises a poly(N-vinylpyrrolidone) hydrogen-bonded a polyphenol (tannic acid) layer. In the compositions, at least one poly(N-vinylpyrrolidone) has conjugated thereon a plurality of manganoporphyrin moieties. The layer-by-layer compositions can be deposited on the cell aggregate surface or deposited on an underlying surface such as that of a silica core which, when removed creates a capsule having a hollow space for the addition of such as a therapeutic agent.

Non-crushable pill formulations and methods of using the formulations are disclosed. A non-crushable pill formulation for preventing unintended use of a drug, comprising a polymer, the polymer forming a polymer backbone of the complex; cross-linkers, the cross-linkers connecting the polymer backbone through covalently bonding to form at least one inner cavity within the complex; and the drug, the drug being trapped either covalently or non-covalently in the at least one inner cavity within the complex, wherein the drug is protected from releasing outside of the complex.

The present disclosure relates to chewing gum or lozenge with cannabinoids and menthol including a liquid-filled chewing gum or lozenge with a chewing gum base shell or lozenge candy shell enclosing an internal void therein and a liquid filling in the void, the liquid-filled chewing gum or lozenge including cannabinoids and menthol.

Disclosed is a therapeutic substance application packet consisting of two or more, different, size ranges of therapeutic substance granules, wherein granules of the different size ranges have different dissolving and exfoliating properties. Further disclosed are an apparatus for application of therapeutic substance application packet and a process for production of same.

The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.

The present invention relates to methods for metabolically loading extracellular vesicles (EVs) with a pharmacological agent. The methods comprise culturing EV source cells in the presence of a metabolic component comprising a pharmacological agent, which is thereby incorporated into the EV-producing cells and subsequently into the EV. The invention further relates to medical uses and compositions of such EVs.